JP2020505046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505046A5 JP2020505046A5 JP2019541082A JP2019541082A JP2020505046A5 JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5 JP 2019541082 A JP2019541082 A JP 2019541082A JP 2019541082 A JP2019541082 A JP 2019541082A JP 2020505046 A5 JP2020505046 A5 JP 2020505046A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- virus
- promoter
- seq
- recombinant virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452075P | 2017-01-30 | 2017-01-30 | |
| US62/452,075 | 2017-01-30 | ||
| PCT/US2018/016025 WO2018140970A1 (en) | 2017-01-30 | 2018-01-30 | Tumor selective tata-box and caat-box mutants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505046A JP2020505046A (ja) | 2020-02-20 |
| JP2020505046A5 true JP2020505046A5 (https=) | 2021-03-11 |
| JP7242534B2 JP7242534B2 (ja) | 2023-03-20 |
Family
ID=62978967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541082A Active JP7242534B2 (ja) | 2017-01-30 | 2018-01-30 | 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190352669A1 (https=) |
| EP (1) | EP3573632B1 (https=) |
| JP (1) | JP7242534B2 (https=) |
| KR (2) | KR102880548B1 (https=) |
| CN (1) | CN110741081B (https=) |
| AU (1) | AU2018212017B2 (https=) |
| BR (1) | BR112019015514A2 (https=) |
| CA (1) | CA3052086A1 (https=) |
| EA (1) | EA201991806A1 (https=) |
| IL (1) | IL268289B2 (https=) |
| MX (1) | MX2019008922A (https=) |
| SG (1) | SG11201906976YA (https=) |
| WO (1) | WO2018140970A1 (https=) |
| ZA (1) | ZA201905070B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| KR102608590B1 (ko) | 2014-09-24 | 2023-12-01 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양 살상 바이러스 및 이의 사용방법 |
| WO2017147269A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
| JP7229173B2 (ja) | 2017-04-10 | 2023-02-27 | エピセントアールエックス，インコーポレイテッド | 組み換えウイルスを産生するための方法 |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| WO2024015876A1 (en) | 2022-07-13 | 2024-01-18 | Epicentrx, Inc. | Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1190901A (en) * | 1999-09-30 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Replication selective adenoviruses for use in cancer therapy |
| WO2002082904A2 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| CN1597939A (zh) * | 2001-11-15 | 2005-03-23 | 杭州中肽生化有限公司 | 多功能抗癌重组腺病毒 |
| CN101319215B (zh) * | 2008-07-01 | 2010-12-22 | 郑骏年 | 人肿瘤特异性Ki67基因启动子 |
| FI20090030A0 (fi) * | 2009-02-02 | 2009-02-02 | Akseli Eetu Hemminki | Onkolyyttiset virukset |
| HUE026386T2 (en) * | 2009-03-02 | 2016-06-28 | Univ California | Tumor-selective adenovirus e1a and e1b mutants |
| KR101427200B1 (ko) * | 2011-11-24 | 2014-08-07 | 주식회사 바이로메드 | 아데노바이러스 생산 신규 세포주 및 그의 용도 |
| FI123955B (en) * | 2011-11-25 | 2014-01-15 | Oncos Therapeutics Ltd | Oncolytic adenovirus |
| US20140350087A9 (en) * | 2012-03-22 | 2014-11-27 | Halozyme, Inc. | Oncovector Nucleic Acid Molecules and Methods of Use |
| RU2696312C2 (ru) * | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| JP7216668B2 (ja) * | 2017-05-26 | 2023-02-01 | エピセントアールエックス，インコーポレイテッド | 導入遺伝子を保持する組換えアデノウイルス |
-
2018
- 2018-01-30 EP EP18744813.9A patent/EP3573632B1/en active Active
- 2018-01-30 US US16/482,049 patent/US20190352669A1/en not_active Abandoned
- 2018-01-30 AU AU2018212017A patent/AU2018212017B2/en active Active
- 2018-01-30 WO PCT/US2018/016025 patent/WO2018140970A1/en not_active Ceased
- 2018-01-30 CN CN201880021788.0A patent/CN110741081B/zh active Active
- 2018-01-30 CA CA3052086A patent/CA3052086A1/en active Pending
- 2018-01-30 IL IL268289A patent/IL268289B2/en unknown
- 2018-01-30 JP JP2019541082A patent/JP7242534B2/ja active Active
- 2018-01-30 EA EA201991806A patent/EA201991806A1/ru unknown
- 2018-01-30 KR KR1020237040310A patent/KR102880548B1/ko active Active
- 2018-01-30 BR BR112019015514-7A patent/BR112019015514A2/pt not_active Application Discontinuation
- 2018-01-30 SG SG11201906976YA patent/SG11201906976YA/en unknown
- 2018-01-30 KR KR1020197025497A patent/KR102607220B1/ko active Active
- 2018-01-30 MX MX2019008922A patent/MX2019008922A/es unknown
-
2019
- 2019-07-31 ZA ZA2019/05070A patent/ZA201905070B/en unknown
-
2025
- 2025-01-17 US US19/030,223 patent/US20250388930A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505046A5 (https=) | ||
| JP2020505049A5 (https=) | ||
| US6677156B2 (en) | Non-adenoviral gene product-based complementing cells for adenoviral vectors | |
| JP6009357B2 (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
| KR101248912B1 (ko) | 항혈관신생 활성을 가지는 재조합 아데노바이러스 | |
| BRPI0418805B1 (pt) | construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos | |
| JP2012016359A (ja) | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター | |
| JP2020513191A5 (https=) | ||
| JP2010525805A5 (https=) | ||
| CN108635380A (zh) | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 | |
| CA2640528A1 (en) | Oncolytic adenoviruses for cancer treatment | |
| JP2014207903A5 (https=) | ||
| US12233096B2 (en) | Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells | |
| JP2008526238A (ja) | 癌標的ウイルスベクター | |
| CN110741081A (zh) | 肿瘤选择性tata盒和caat盒突变体 | |
| JP2024522074A5 (https=) | ||
| WO2012163119A1 (zh) | 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用 | |
| JP2020528890A5 (https=) | ||
| NO330666B1 (no) | Selektivt replikerende, rekombinant virusvektor, farmasoytisk formulering, fremgangsmate for dreping av en celle ex vivo med en reaksjonsveimangel, anvendelse av en selektivt replikerende viral vektor for fremstilling av et farmasoytisk preparat, samt fremgangsmate for fremstilling av en selektivt replikerende viral vektor. | |
| CN103562386A (zh) | Reic表达腺病毒载体 | |
| Liu et al. | Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L | |
| JP6235697B2 (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| Wu et al. | Viral delivery for gene therapy against cell movement in cancer | |
| Hemminki | From molecular changes to customised therapy | |
| Zhu et al. | Targeting gene expression to tumor cells with loss of wild-type p53 function |